Synthesis and cytotoxic evaluation of the first trans-palladium(II) complex with naturally occurring alkaloid harmine

European Journal of Medicinal Chemistry

Volumn 33, Issue 10, 1998, Pages 817-820

  Al Allaf, Talal A K ^a,b   Rashan, Luay J ^a,b  

^a APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

^b UNIVERSITY OF MOSUL   (Iraq)

Author keywords

Complex; Cytotoxicity; Harmine; Trans palladium(II)

Indexed keywords

ALKALOID; HARMINE; PALLADIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG SYNTHESIS; LIGAND BINDING;

EID: 0032321685     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80033-6     Document Type: Article

References (21)

1. [1] Rosenberg B., van Camp L., Trosko J.E., Mansour V.H., Nature 222 (1969) 383-386.
2. [2] Harrap K.R., Cancer Treat. Rev. Rep 12A (1985) 21-33.
3. [3] Sanofi Winthrop, Eloxatine (Oxaliplatin), The 7th International Congress on Anti-Cancer Treatment, 3-6 February 1997, Paris, France.
4. [4] Kelland L.R., Crit. Rev. Oncol. Hematol. 15 (1993) 191-219.
5. [5] Weiss R.B., Christian M.C., Drugs 46 (1993) 360-377.
6. [6] Al-Allaf T.A.K., Ayoub M.T., Rashan L.J., J. Inorg. Biochem. 38 (1990) 47-56.
7. [7] Al-Allaf T., Castan P., Turpin R., Wimmer S., CR Acad. Sci. Paris 314(11) (1992) 1029-1033.
8. [8] Al-Allaf T.A.K., Rashan L.J., Kuzaie R.F., Halaseh W.F., Asian J. Chem. 8(3) (1996) 505-512.
9. [9] Al-Allaf T.A.K., Rashan L.J., UK Pat. Appl. GB 2 303 627 a (1997).
10. [10] Rashan L.J., Al-Allaf T.A.K., Ayoub M.T., Adaay M.H., UK Pat. Appl. GB 2 304 712 a (1997).
11. [11] (a) Rashan L.J., Al-Allaf T.A.K., 6th International Congress on Anti-Cancer Treatment, 6-9 February, Paris, France, 1996;
12. (b) Al-Allaf T.A.K., Rashan L.J., 7th International Congress on Anti-Cancer Treatment, 3-6 February, Paris, France, 1997.
13. [12] Farrell N., Ha T.T.B., Souchared J.P., Wimmer F.L., Cross S., Johnson N.P., J. Med. Chem. 32 (1989) 2240-2241.
14. [13] Van Beusichem M., Farrell N., Inorg. Chem. 31 (1992) 634-639.
15. [14] (a) Sherman S.E., Gibson D., Wang A.H.J., Lippard S.J., Science 230 (1985) 412-417;
16. (b) Kozelka J., Petsko G.J., Lippard S.J., J. Am. Chem. Soc. 107 (1985) 4079-4081.
17. [15] Al-Allaf T., Ayoub M., Rashan L., Dirasat (Jordan) 21B(1) (1994) 128-136; Chem. Abst. 122:10331.
18. [15] Al-Allaf T., Ayoub M., Rashan L., Dirasat (Jordan) 21B(1) (1994) 128-136; Chem. Abst. 122:10331.
19. [16] Price J.H., Williamson A.N., Schramm R.F., Wayland B.B., Inorg. Chem. 11 (1972) 1280-1284.
20. [17] Mosmann T., J. Immunol. Meth. 65 (1983) 55-63.
21. [18] Tsai C.M., Gazdar A.F., Allegra C., Perng R.P., Kramer B.S., Int. J. Cancer 46 (1990) 101-105.